Issue: October 2016
October 13, 2016
2 min watch
Save

VIDEO: Luminate meets primary, secondary endpoints in phase 2b trial

Issue: October 2016
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — At the Ophthalmology Innovation Summit here, Vicken Karageozian, MD, president and chief medical officer of Allegro Ophthalmics, discusses the results of the phase 2b DEL MAR clinical trial of Luminate for treating diabetic macular edema.
In the controlled, double-masked, multicenter, dose-ranging study, Luminate (ALG-1001) met both its primary endpoint for visual acuity and secondary endpoint for reduction in central macular thickness as measured by OCT.